Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Auric Goldfinger's Short List -- Ignore unavailable to you. Want to Upgrade?

To: StockDung who wrote (10663)	11/3/2002 4:39:20 AM
From: afrayem onigwecher	Read Replies (1) \| Respond to of 19428

The Wall Street Transcript publishes: Special MedTech Conference Opportunity !!!! Have direct access to leading analysts and CEOs at our special MedTech Conference in NYC November 14th! Click for information or call us today at (212) 952 7454 . Specialty Chemicals Issue 5 analysts and top management from 5 sector firms examine the sector in this 47-page Specialty Chemicals Issue Let the best minds of Wall Street pick your stock CEO of GeneMax details their exciting TAP cancer technology Ronald L. Handford, GeneMax Corp RONALD L. HANDFORD is President and CEO of GeneMax Corp For Subscribers twst.com Get the complete article now! Six Analysts and top management from seventeen sector firms examine the Specialty Pharmaceuticals sector in this 95 - page Special Focus - Specialty Pharmaceuticals Issue from The Wall Street Transcript available at (212/952-7433) or www.twst.com TWST: Could you give us a short introduction to GeneMax (OTC:GMXX.OB)? Mr. Handford: We are a now public biotech company in the area of cancer immunotherapy. This is based on technologies we’ve licensed in from the University of British Columbia. GeneMax was founded in 1999 specifically to acquire these technologies and was funded through private capital, largely angel capital, for the first two years of its existence. In the spring of 2002, we made an arrangement with a public OTC Bulletin Board company called Eduverse.com to affect a reverse merger and put together GeneMax and Eduverse to create a listed company. That transaction has proceeded to the point where we expect to fully close that acquisition and merger this month. We already closed the first phase in July, which was for the US and offshore shareholders. The British Columbia shareholders who are merging in under a separate document should be fully completed by the end of August. TWST: How strong is the balance sheet? When you look at your need for cash need, are you able to meet it? Mr. Handford: We are in the process of a financing right now, which is being targeted as a private placement. So there will be institutional and individual investors coming into this round. We are just putting the financing together right now, so we expect to have this closed off by the middle of September. That should provide for the next year’s activities. We immediately will be following that with another financing intended at a higher price, and that should see us right through the Phase I clinical trials. So it’s our objective to put this company in a financial position where it has over two year’s cash on the balance sheet as soon as possible. TWST: Are there other elements of the pipeline in the thrust of this company? Mr. Handford: We see multiple applications of TAP beyond the initial cancer indication. And that’s the subject of ongoing research in the laboratory, as well as the intellectual property we’re developing. Beyond that, as I mentioned, we have the peptide transfer assay technology, which is a tool that we can use to build out a pipeline of immune modulating compounds, diversifying the risk, both the company and for the investors. Also there is our ongoing strong relationship with the University of British Columbia and we are in discussions with them on an ongoing basis about other technologies that would be complementary to the ones we’ve already in-licensed to bring those into the pipeline. Another aspect would be approaches we’ve had from other companies as to collaborative deals or licensing or sub-licensing in other technologies that they have. So there are many routes to build out our pipeline, but about 85% of our corporate focus and resource allocation will be to moving our TAP into the clinic because we think this will build up the biggest valuation milestone for the company. We recognize the need to diversify risk and to build out the pipeline and we’ll certainly be spending some time and resources on that. 1) Specialty Pharmaceuticals - In an in-depth (11,600) words) Analyst Roundtable, Dr. Steven B. Gerber, CIBC World Markets, Marc Goodman, Morgan Stanley, Maria Legatos-Phillips, Banc of America Securities, Erick Lucera, Independence Investment LLC, David Steinberg, Deutsche Bank Securities, examine the outlook for the sector and share specific stock recommendations. 2) Pharmaceuticals - In an in-depth (2,900 words) Analyst Interview, Rodney C. Singleton, G.W. Henssler & Associates, Ltd., examines the outlook for the sector and share specific stock recommendations. 3) CEO interviews (average 2,500 words). Top management of 17 - sector firms examine the outlook for their firm and the sector. twst.com